Institution Directory

Clinical trials at Ohio State University Wexner Medical Center

Sites in Columbus, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 12:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1591

Shown on this page

Current sort

Live official records

Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions: Bicalutamide, Biopsy Procedure, Biospecimen Collection, Questionnaire Administration, Transurethral Resection of Bladder Tumor; Drug · Procedure · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • Bethesda, Maryland + 3 more

Conditions: Moderate Aortic Valve Stenosis
Interventions: Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 65 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more

Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Interventions: Biospecimen Collection; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Carboplatin, Lumpectomy, Mastectomy, Paclitaxel; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 9 more

Conditions: Lewy Body Dementia Psychosis
Interventions: ACP-204; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 55 Years to 84 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 18
States / cities: Irvine, California • Aventura, Florida • Boca Raton, Florida + 13 more

Conditions: Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation
Interventions: Not listed
Lead sponsor: CoMind Technologies Limited; Industry
Eligibility: 18 Years and older
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Phoenix, Arizona • Sacramento, California • Wilmington, Delaware + 14 more

Conditions: Breast Inflammatory Carcinoma
Interventions: Biospecimen Collection, Olaparib, Radiation Therapy, Survey Administration; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 214
States / cities: Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 174 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Interventions: OrcaGraft (Orca-Q); Biological
Lead sponsor: Orca Biosystems, Inc.; Industry
Eligibility: 12 Years to 78 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Duarte, California • Sacramento, California • Stanford, California + 9 more

Conditions: Friedreich's Ataxia (FA)
Interventions: SGT-212; Drug
Lead sponsor: Solid Biosciences Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Los Angeles, California • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk, Gestational Diabetes, Gestational Diabetes Mellitus in the Puerperium
Interventions: Immediate inpatient postpartum OGTT, Standard of care 4-12 week postpartum OGTT; Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 12 more

Conditions: Lewy Body Dementia Psychosis
Interventions: ACP-204, Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 55 Years to 84 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 30
States / cities: Irvine, California • Aurora, Colorado • Washington D.C., District of Columbia + 23 more

About this Ohio State University Wexner Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Ohio State University Wexner Medical Center in Columbus, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Ohio State University Wexner Medical Center

Filter and sort this campus

Live official records

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

Evolut™ EXPAND TAVR II Pivotal Trial

A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

CoMind Early Feasibility Study

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

About this Ohio State University Wexner Medical Center institution page